Key result
Audit of NCCN-cited breast cancer trials reveals infrequent cardiovascular safety planning.
Why the study?
Cardiovascular and venous thromboembolism risks vary across systemic breast cancer therapies, but NCCN-cited trials underpinning recommendations may embed inconsistent safety surveillance.
Cardiovascular and VTE safety planning in NCCN-cited breast cancer trials is heterogeneous and concentrated in HER2-directed evidence, highlighting a need for class-adapted surveillance standards to prevent underestimation of cardiotoxicity.
Answers are grounded in this paper and cite their sources.
May underestimate cardiotoxicity outside HER2 trials; leaves open whether standardized CVERQ-BC protocols improve future trial safety planning.
e24022 Background: Cardiovascular (CV) and venous thromboembolism (VTE) risks differ across systemic breast cancer therapies. NCCN-cited trials underpin treatment recommendations but may embed inconsistent CV and VTE safety surveillance. Methods: Audit of phase II–III systemic-therapy trials cited in NCCN Breast Cancer Guidelines. We created a novel scoring system CVERQ-BC (Cardiovascular evaluation and reporting quality in Breast Cancer) (scored 0–12), capturing reported baseline CV risk; baseline imaging; prespecified serial imaging; baseline ECG; troponin/NP strategy; quantitative CV endpoint definitions; prespecified CV endpoints; central adjudication; CV AE grading; inclusion of stable CVD; BP monitoring with HTN criteria; CV dose-mod/hold rules. VTE score (0–3) captured validated VTE risk models, protocolized prophylaxis, and prespecified objective VTE endpoints. CVERQ-BC scoring was based on review of trial publications, full texts, study protocols, and trial registrations. Two independent reviewers scored each trial, with discrepancies resolved by consensus. Analyses were descriptive with exploratory comparisons by class, era, and sponsor. Results: We included 129 unique trials (1990–2026); 49.6% were industry-sponsored. Median CVERQ-BC was 2 (IQR 2–4); 56.6% scored ≤2 and 6.2% ≥8. Key CV elements were infrequently reported: baseline CV risk (28.7%), baseline imaging (32.6%), prespecified follow-up imaging (24.8%), ECG surveillance (10.9%), biomarker strategy (3.1%), prespecified CV endpoints (26.4%), and central adjudication (10.9%). CVERQ-BC did not differ by sponsor type (p = 0.39) or era among industry trials (p = 0.31). By class (median [IQR]): HER2-directed 6.0 [4.5–7.5], anthracycline 3.0 [2.0–6.0], taxane 3.0 [2.0–6.0], fluoropyrimidine 2.0 [2.0–5.0], alkylator 2.0 [1.25–5.0], platinum 2.0 [2.0–3.5], endocrine 2.0 [2.0–4.0], CDK4/6 inhibitor 2.0 [2.0–3.5]. In HER2-directed trials, baseline and serial cardiac imaging was reported in 77.8% (21/27), explicit quantitative CV endpoint definitions in 77.8% (21/27), and prespecified CV endpoints in 70.4% (19/27). Outside HER2-directed evidence, mechanism-aligned safety domains were uncommon, with QTc or ECG surveillance in QT-liability tyrosine kinase inhibitor and CDK4/6 inhibitor trials, blood pressure criteria in VEGF or VEGFR-directed regimens, and ischemia monitoring in fluoropyrimidine trials each reported in 20% or fewer studies. Conclusions: Reported CV/VTE safety planning in NCCN-cited trials is heterogeneous and concentrated in HER2-directed evidence. Without guideline-specified class-adapted surveillance standards (and possible under-reporting), variability may underestimate cardiotoxicity and limit generalizability to patients with baseline CVD. CVERQ-BC provides a reproducible, class-adapted checklist for trial protocols, reporting, and guideline citation.
No takes yet. Share an insight, caveat, or question.
Bowen et al. (2026) conducted a review in Breast Cancer (n=129). An audit of 129 NCCN-cited breast cancer trials demonstrated infrequent cardiovascular safety planning, with a median CVERQ-BC score of 2 (IQR 2-4) out of 12.
Synapse has enriched 10 related papers. Consider them for comparative context: